Skip to content
Search

Latest Stories

Solihull pharmacist struck off for illegally supplying a prescription-only medicine to the Caribbean

The General Pharmaceutical Council (GPhC) has removed a pharmacist from its register who black-marketed 'zolpidem' along with another pharmacist between 2015 and 2016.

Dean Zainool Dookhan, a pharmacist first registered with the Royal Pharmaceutical Society of Great Britain on 18 October 2004 and whose registration was later transferred to the General Pharmaceutical Council under registration number 2059808, was jailed last year for exporting 20,000 packets of zolpidem to the Caribbean.


While hearing the case on 24-25 May, GPhC’s Fitness to Practise Committee stated that “removal of the Registrant’s name from the register is the appropriate and proportionate response to his convictions.”

“The public interest includes protecting the public, maintaining public confidence in the profession, and maintaining proper standards of behaviour. The Committee is entitled to give greater weight to the public interest than the Registrant’s own interest in remaining on the register.”

“The Committee recognises the sanction has a punitive effect in that the Registrant’s ability to practise and earn an income as a pharmacist and 28 his professional reputation will be curtailed; it will be five years before he can seek restoration to the register. However, that is the price he must pay for failing to comply with the fundamental tenets of his profession.”

It also added: “Removing a registrant’s registration is reserved for the most serious conduct… The committee should consider this sanction when the registrant’s behaviour is fundamentally incompatible with being a registered professional.”

Dean and another pharmacist were found pleaded guilty of possessing a medicinal product, Zolpidem, for the purpose of wholesale distribution otherwise under a licence and that is an offence contrary to the Human Medicines Regulation of 2012 and an offence of supplying a controlled drug of class C, Zolpidem.

Zolpidem is a sleeping tablet and is a class C controlled drug. It is prescribed on a short-term basis to adults who suffer from insomnia. It can only be supplied lawfully to an individual on prescription and on a wholesale basis with the appropriate licence with the MHRA.

Between 1 September 2015 and 13 May 2016, both pharmacists acted together, in selling and exporting Zolpidem on a wholesale basis to a man called in Trinidad.

Dean’s actions were discovered when the owners of Northbrook Pharmacy became suspicious of the unusually large quantity of orders of zolpidem and an MHRA investigation was commenced.

He was given a 27-month prison sentence on July 12, 2021, at Birmingham Crown but was released early, on a licence, from prison on 14 April 2022. He remains under the 14 supervision of the Probation Service, being subject to a home curfew. His licence is due to expire on 11 October 2023.

The decision of removal from the register will be effective after 24th June, if no appeal against the decision is lodged by Dean until the said date.

More For You

Walgreens Boots Alliance acquired by Sycamore in deal

Walgreens Boots Alliancehas entered into “a definitive agreement” to be acquired by Sycamore Partners

Gettyimages

Walgreens Boots Alliance acquired by Sycamore in £18.3 billion deal

Walgreens Boots Alliance(WBA) has entered into “a definitive agreement” to be acquired by Sycamore Partners, a private equity firm specializing in retail, consumer and distribution-related investments.

“The total value of the transaction represents up to $23.7 billion (£18.3 billion),” the company announced late last night (6).

Keep ReadingShow less
Professor Sir Stephen Powis at a press briefing

Professor Sir Stephen Powis, was appointed national medical director of NHS England in 2018

NHS

NHS England’s top doctor to step down following Amanda Pritchard’s resignation

Just a week after NHS England chief executive Amanda Pritchard announced her resignation, the organisation’s national medical director, Professor Sir Stephen Powis, has confirmed he will step down this summer after more than seven years in the role.

In a statement released on Thursday, Professor Powis revealed that he had informed Pritchard of his intention to leave in a letter back in January.

Keep ReadingShow less
PDA calls on GP practices to use funding boost to improve job security for pharmacists

Now, it is time to focus on the community pharmacy contract

gettyimages

PDA urges GP practices to ensure funding boost supports employed pharmacists

The Pharmacists' Defence Association (PDA) has called on GP practicesto ensure that all healthcare professionals they employ, including pharmacists, benefit from the 7.2% funding boost they received under a newly agreed contract.

GP employers are encouraged to improve “job security, pay and conditions” for employees with this increased funding.

Keep ReadingShow less
Fourth Shift: Investment in Innovative Medicines Crucial for NHS 10-Year Plan Success

Medicines should be viewed as an investment rather than a cost

gettyimages

ABPI wants to see a ‘fourth shift’ in NHS 10-Year Health Plan


The Association of the British Pharmaceutical Industry (ABPI) has called on the government to increase investment in innovative medicines and vaccines, describing it as a crucial “fourth shift” necessary to ensure the NHS is fit for the future.

Keep ReadingShow less
Lawrence Tallon named new MHRA chief executive

Lawrence Tallon

Photo credit: Sciana Network

Lawrence Tallon named new MHRA chief executive

Lawrence Tallon has been appointed as the new chief executive officer of the Medicines and Healthcare products Regulatory Agency (MHRA), effective 1 April 2025.

He will succeed Dame June Raine DBE, who is retiring after leading the agency since 2019.

Keep ReadingShow less